Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)

NCT02942576 is registered in ClinicalTrials.gov with Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company as lead sponsor.

NCT NCT02942576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02942576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)
Lead sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase
Phase 3
Overall status
Completed
Start date
March 21, 2017
Completion date
September 24, 2018
Enrollment
632 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation